TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

HUMABODY

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

HUMABODY

ST13

US500000079179556

Classe

1, 5, 40, 42

Pedido

79179556

Registro

5158366

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

55

Atualização mais recente

15/03/2026

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

1, 5, 40, 42

Data de depósito

17/12/2014

Data de registro

14/03/2017

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

27/06/2024

Última transação

15/03/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

707

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

99

Localização do titular

Cambridge, GB

Examinador

POLLACK, ALISON FRIEDBERG

Localização atual

Historical data usage

Titulares e representantes

Titulares

Crescendo Biologics Limited

Representantes

Rebecca Liebowitz VENABLE LLP

Classificação técnica

Classes Nice

Classe 1Classe 5Classe 40Classe 42

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 1

chemicals used in industry and science; [ chemical test kits for in vitro testing for laboratory research purposes; ] biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for in vitro scientific and laboratory research use; biochemicals, namely, monoclonal antibodies and antibody fragments for in vitro scientific and laboratory research use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products

Classe 5

pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; veterinary preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; antibody fragments being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases] ; antibody therapeutics in the nature of therapeutic agents for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; medical diagnostic reagents and veterinary diagnostic reagents in the nature of antibodies and antibody fragments; antibodies and antibody fragments being therapeutic pharmaceuticals for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] and or use in the manufacture of therapeutic products

Classe 40

[ Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments ]

Classe 42

[ Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; Scientific laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field of antibodies and antibody fragments for medical and veterinary purposes; engineering of antibodies and antibody fragments; scientific services, namely, drug discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design ]

Publicações

Histórico de despachos e eventos da marca no USPTO.

55 publicações encontradas

REM4

COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED

14/03/2026

INNP

PARTIAL INVALIDATION PROCESSED BY THE IB

20/06/2025

INPS

PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

12/05/2025

INPC

INVALIDATION PROCESSED

12/05/2025

LIMN

LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED

12/05/2025

INPR

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED

27/02/2025

RNWL

INTERNATIONAL REGISTRATION RENEWED

12/12/2024

RHRD

RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED

08/11/2024

NA71

NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED

27/06/2024

71.P

REGISTERED - PARTIAL SEC 71 ACCEPTED

27/06/2024

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

07/05/2024

LIMN

LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED

27/10/2023

ES71

TEAS SECTION 71 RECEIVED

13/09/2023

RHRD

RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED

19/08/2023

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

14/03/2022

NREP

NEW REPRESENTATIVE AT IB RECEIVED

07/12/2017

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

14/07/2017

FICS

FINAL DISPOSITION NOTICE SENT TO IB

22/06/2017

FIMP

FINAL DISPOSITION PROCESSED

22/06/2017

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

14/06/2017

R.PR

REGISTERED-PRINCIPAL REGISTER

14/03/2017

ETOP

EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED

03/02/2017

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

18/11/2016

ETOF

EXTENSION OF TIME TO OPPOSE RECEIVED

18/10/2016

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

20/09/2016

PUBO

PUBLISHED FOR OPPOSITION

20/09/2016

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

31/08/2016

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

31/08/2016

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

31/08/2016

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

17/08/2016

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

09/08/2016

XAEC

EXAMINER'S AMENDMENT ENTERED

09/08/2016

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

09/08/2016

GNEA

EXAMINERS AMENDMENT E-MAILED

09/08/2016

CNEA

EXAMINERS AMENDMENT -WRITTEN

09/08/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

08/08/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

08/08/2016

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

08/08/2016

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

29/07/2016

GNFR

FINAL REFUSAL E-MAILED

29/07/2016

CNFR

FINAL REFUSAL WRITTEN

29/07/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

15/07/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

15/07/2016

ALIE

ASSIGNED TO LIE

15/07/2016

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

11/07/2016

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

11/07/2016

RFNT

REFUSAL PROCESSED BY IB

01/02/2016

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

11/01/2016

RFRR

REFUSAL PROCESSED BY MPU

11/01/2016

MAFR

APPLICATION FILING RECEIPT MAILED

08/01/2016

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

06/01/2016

CNRT

NON-FINAL ACTION WRITTEN

05/01/2016

DOCK

ASSIGNED TO EXAMINER

04/01/2016

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

04/01/2016

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

03/01/2016

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace HUMABODY ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.